The FY2025 (Dec) proxy of Arvinas names 16 peer companies for pay. Among Arvinas and these peers, CEO pay was 3rd highest of 6 and total shareholder return was the lowest of 6.
3rd highest of 6in Arvinas and its pay peers, FY2025 (Dec) by CEO pay:
$4.2M$27.8M
6th highest of 6in Arvinas and its pay peers, FY2025 (Dec) by total shareholder return:
$14$414
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| Arcus Biosciences | ||
| Intellia Therapeutics | ||
| Relay Therapeutics | ||
| Regenxbio | ||
| Alector, Inc. | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Biohaven | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Denali Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Erasca | Not disclosed | Not disclosed |
| KalVista Pharmaceuticals, Inc. () | Not disclosed | Not disclosed |
| Prothena Corporation plc () | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
16 companies
Changes by year
FY2025 (Dec) proxy
- RemovedCerevel Therapeutics, Inc.pay peer groupdue to acquisition, as applicable
- RemovedDeciphera Pharmaceuticals, Inc.pay peer groupdue to acquisition, as applicable
- RemovedFate Therapeutics, Inc.pay peer groupdue to acquisition, as applicable
- RemovedMirati Therapeutics, Inc.pay peer groupdue to acquisition, as applicable
- RemovedRevolution Medicinespay peer groupdue to acquisition, as applicable
- RemovedZentalis Pharmaceuticals, Inc.pay peer groupdue to acquisition, as applicable
FY2024 (Dec) proxy
- RemovedIntra-Cellular Therapies, Inc.pay peer groupdue to acquisition, as applicable
- RemovedKaruna Therapeutics, Inc.pay peer groupdue to acquisition, as applicable
- RemovedLegend Biotech, Inc.pay peer groupdue to acquisition, as applicable
- RemovedReata Pharmaceuticals, Inc.pay peer groupdue to acquisition, as applicable
FY2023 (Dec) proxy
- RemovedDicerna Pharmaceuticals, Inc.pay peer groupdue to acquisition, as applicable
- RemovedRubius Therapeutics, Inc.pay peer groupdue to acquisition, as applicable
- RemovedTurning Point Therapeutics, Inc.pay peer groupdue to acquisition, as applicable
- RemovedZymeworkspay peer groupdue to acquisition, as applicable
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.